Effect of On-Line Hemodiafiltration with Endogenous Reinfusion (HFR) on the Calcium-Phosphorus Metabolism: Medium-Term Effects

Abstract

Aim

The purpose of the study was to examine the effect of hemodiafiltration with endogenous reinfusion (HFR) compared to hemodialysis (HD) on 28 uremic patients with secondary hyperparathyroidism (2HPT) but positively selected for good and stable control of phosphatemia in order to evaluate the independent effects of dialysis treatments on bone turnover metabolism. Methods: The study was divided into 3 periods of observation: a) HD for three months; b) HFR for three months; c) HFR for a further 3 months. We analysed the trend of: whole PTH, 1–84 PTH, 7–84 PTH, alkaline phosphatase and its bone isoenzyme, total and ionised calcium, phosphatemia, dose of phosphate binder agents, β2-microglobulin, CRP. All the variations found were evaluated through mean values ± SD, t-tests, multivariate analysis.

Results

We observed a deceleration in bone turnover characterized by a reduction of the total and bone alkaline phosphatase (IU/mL) from 92.3 ± 82.8 and 35.8 ± 49.8 at the end of HD to 63.4 ± 23.9 and 16.0 ± 8.7 at the end of HFR, respectively, and 1–84 PTH from 317.5 ± 264.6 pg/mL at the end of HD to 287.5 ± 258.9 pg/mL at the end of the 3^rd month of HFR. β2-microglobulin was reduced from 32.9 ± 16.1 mg/L at the end of HD to 26.4 ± 8.1 mg/L already at the end of the first three months of HFR. CRP was reduced from 2.5 ± 2.6 mg/dL at the beginning of the study to 1.3 ± 1.7 mg/dL at the end of HFR. There were no differences with regard to: dialytic efficiency, nutritional status, calcemia, phosphatemia (maintained in the K-DOQI range for the entire duration of the study), also thanks to more careful use of phosphate chelating agents.

Conclusion

We are of the opinion that HFR - essentially thanks to the use of ultrapure endogenous infusate - induces a deceleration in bone turnover due to 2PHT. In addition, phosphate substraction in HFR is better compared to HD, thanks to the improvement of the anti-inflammatory conditions by removing the cytokines harmful to bone metabolism and excluding a priori the negative effects related to hyperphosphatemia. (Int J Artif Organs 2006; 29: 1042–52)

Keywords

HFR On-line hemodiafiltration with endogenous reinfusion Bone metabolism Cytokines Dialysis microinflammation

Get full access to this article

View all access options for this article.

References

Zehnder

, Gutzwiller

J.P.

, Renggli

Hemodiafiltration: A new treatment option for hyperphosphatemia in hemodialysis patient.

Clin Nephrol 1999; 52: 152–9.

Zucchelli

, Santoro

Inorganic phosphate removal during different dialytic procedures.

Int J Artif Organs 1987; 10: 173–8.

Fischbach

, Hamel

, Simeoni

, Geisert

Phosphate dialytic removal: Enhancement of phosphate cellular clearance by biofiltration (with acetate-free buffer dialysate).

Nephron 1992; 62: 155–60.

Ratanarat

, Brendolan

, Volker

. Phosphate kinetics during different dialysis modalities. Blood Purif 2005; 23: 83–90.

Pohlmeier

, Vienken

Phosphate removal and hemodialysis conditions.

Kidney Int Suppl 2001; 78: S190–4.

Minutolo

, Bellizzi

, Cioffi

. Postdialytic rebound of serum phosphorus: Pathogenetic and clinical insights. J Am Soc Nephrol 2002; 13: 1046–54.

DeSoi

C.A.

, Umans

J.C.

Phosphate kinetics during high-flux hemodialysis.

J Am Soc Nephrol 1993; 4: 1214–8.

Messa

, Gropuzzo

, Cleva

. Behaviour of phosphate removal with different dialysis schedules. Nephrol Dial Transplant 1998; 13(suppl 6): S43–8.

Gotch

F.A.

, Froilan

, Sergeyeva

. A kinetic model of inorganic phosphorus mass balance in hemodialysis therapy. Blood Purif 2003; 21: 51–7.

10.

Mallamaci

, Tripepi

, Zoccali

Leptin in end stage renal disease (ESRD): A link between fat mass, bone and the cardiovascular system.

J Nephrol 2005; 4: 464–8.

11.

Costantini

, Meschini

. Hemodiafiltration with endogenous reinfusion (HFR): Biochemical and gas-analytical analysis of the “regenerated” ultrafiltrate. G Ital Nefrol 2004; 21(Suppl 30): S75–9.

12.

Kunitomo

, Lowrie

E.G.

, Kumazawa

. Controlled ultrafiltration with hemodialysis: Analysis of coupling between convective and diffusive mass tansfer in a new HD-UF system. Trans Am Soc Artif Intern Organs 1977; 23: 234–43.

13.

De Francisco

A.L.M.

, Ghezzi

P.M.

, Brendolan

. Hemodiafiltration with on line regeneration of the ultrafiltrate. Kidney Int Suppl 2000; 76: S66–71.

14.

Bolasco

P.G.

, Ghezzi

P.M.

, Ferrara

. New method for the phosphate kinetics estimation during hemodialysis and on-line hemodiafiltration with endogenous reinfusion (HFR). Blood Purif 2006; 24: 301–8.

15.

Panichi

, Manca-Rizza

, Paletti

. Effects on inflammatory and nutritional markers of haemodiafiltration with online regeneration of ultrafiltrate (HFR) vs on line haemodiafiltration: A cross-over randomized multicentre trial. Nephrol Dial Transplant 2006; 21: 756–62.

16.

National Kidney Foundation.

K/DOQI Clinical Practice guidelines: Bone metabolism and disease in chronic kidney disease.

Am J Kidney Dis 2003; 42(Suppl 4): S1–201.

17.

Faugere

M.C.

, Gao

, Genz

, Cantor

T.L.

, Malluche

H.H.

The 1-84: 7-84 ratio for determination of bone turnover in chronically dialyzed patients. Abstract of Annual American Society Toronto.

J Am Soc Nephrol 2000; 11: 554A.

18.

Malluche

H.H.

, Monier-Faugere

M.C.

PTH 1-84, PTH fragments and bone turnover.

Am J Kidney Dis 2003; 41: 1127.

19.

Lehmann

, Stein

, Huller

. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int 2005; 68: 1206–14.

20.

Flanigan

M.J.

, Fangman

, Lim

V.S.

Quantitating hemodialysis: A comparison of three kinetic models.

Am J Kidney Dis 1991; 17: 295–302.

21.

Delmez

J.A.

, Slatopolsky

Hyperphosphatemia: Its consequences and treatment in patient with chronic renal disease.

Am J Kidney Dis 1992; 19: 303–17.

22.

Alfrey

A.C.

The role of abnormal phosphorus metabolism in the progression of chronic kidney disease and metastatic calcification.

Kidney Int Suppl 2004; 90: S13–7.

23.

Hsu

C.H.

Are we mismanaging calcium and phosphate metabolism in renal failure?

Am J Kidney Dis 1997; 29: 641–9.

24.

Block

G.A.

, Hulbert-Shearon

T.E.

, Levin

N.W.

. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patient: A national study. Am J Kidney Dis 1998; 31: 607–17.

25.

Block

How should hyperphosphatemia be managed in dialysis patients?

Semin Dial 2002; 15: 315–7.

26.

Spalding

E.M.

, Chamney

P.W.

, Farrington

Phosphate kinetics during hemodialysis: Evidence for biphasic regulation.

Kidney Int 2002; 61: 655–67.

27.

Pogglitsch

, Estelberger

, Petek

. Relationship between generation and plasma concentration of inorganic phosphorus. In vivo studies on dialysis patients and in vitro studies on erythrocytes. Int J Artif Organs 1989; 12: 524–32.

28.

De Francisco

A.L.M.

, Pinera

, Heras

. Hemodiafiltration with on-line endogenous reinfusion. Blood Purif 2000; 18: 231–6.

29.

De Francisco

A.L.M.

, Botella

, Escallada

. Hemodiafiltration with sorbent-regenerated ultrafiltrate as replacement fluid: A multicenter study. Nephrol Dial Transplant 1997; 12: 528–34.

30.

Schindler

Elimination of cytokines from plasma by ultrafiltration using conventional polysulfone or Diapes membranes.

Contrib Nephrol 2003; 138: 37–42.

31.

Cole

, Bellomo

, Davenport

. The effect of couplet hemofiltration and adsorption on inflammatory cytokines in an ex vivo model. Nephrol Dial Transplant 2002; 17: 1950–6.

32.

Girndt

, Kohler

Interleukin-10 (IL-10): An update on its relevance for cardiovascular risk.

Nephrol Dial Transplant 2003; 18: 1976–9.

33.

Sonikian

M.A.

, Pani

I.T.

, Iliopoulos

A.N.

. Metabolic acidosis aggravation and hyperkaliemia in hemodialysis patients treated by sevelamer hydrochloride. Ren Fail 2005; 27: 143–7.